Anebulo Pharmaceuticals, Inc. Common Stock
Symbol: ANEB (NASDAQ)
2.74
▲ (1.86%) 0.050
Company Description:
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
Key Stats
- Today's Open: $2.71
- Today's High: $2.78
- Today's Low: $2.705
- Today's Volume: 20.27K
- Yesterday Close: $2.69
- Yesterday High: $2.85
- Yesterday Low: $2.62
- Yesterday Volume: 52.83K
- Last Min Volume: 2
- Last Min High: $2.74
- Last Min Low: $2.74
- Last Min VWAP: $2.74
Company Profile
- Name: Anebulo Pharmaceuticals, Inc. Common Stock
- Website: https://www.anebulo.com
- Listed Date: 2021-05-07
- Location: LAKEWAY, TX
- Market Status: Active
- CIK Number: 0001815974
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $110.52M
- Round Lot: 100
- Outstanding Shares: 41.08M
- Asset Type: CS
RECENT FILINGS FOR ANEB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-14 | SC 13E3/A | View |
| 2025-10-10 | PRER14A | View |
| 2025-09-29 | 10-K | View |
| 2025-09-29 | 8-K | View |
| 2025-09-26 | S-8 POS | View |
| 2025-09-26 | S-8 POS | View |
| 2025-09-23 | EFFECT | View |
| 2025-09-23 | EFFECT | View |
| 2025-09-19 | POS AM | View |
| 2025-09-19 | POS AM | View |
| 2025-09-15 | SC 13E3/A | View |
| 2025-09-15 | PRER14A | View |
| 2025-09-12 | 8-K | View |
| 2025-07-23 | 8-K | View |
| 2025-07-23 | SC 13E3 | View |
| 2025-07-23 | PRE 14A | View |
| 2025-05-15 | S-8 | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-13 | 8-K | View |
| 2025-04-15 | 8-K | View |
Latest News on ANEB